Ozanimod

Drug Profile

Ozanimod

Alternative Names: RPC-1063

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator The Scripps Research Institute
  • Developer Receptos
  • Class Indenes; Nitriles; Oxadiazoles; Small molecules
  • Mechanism of Action Sphingosine 1 phosphate receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Multiple sclerosis; Ulcerative colitis
  • Phase II Crohn's disease

Most Recent Events

  • 01 Feb 2017 Celgene completes the phase III SUNBEAM trial for Multiple sclerosis (Treatment-experienced) in USA, Belarus, Bosnia and Herzegovina, Bulgaria, Canada, Croatia, Estonia, Georgia, Germany, Hungary, Latvia, Lithuania, Moldova, Netherlands, New Zealand, Poland, Portugal, Romania, Russia, Serbia, Spain, Sweden, Ukraine and United Kingdom (NCT02294058)
  • 09 Jan 2017 Celgene announces intention to submit NDA for Multiple sclerosis in 2017
  • 01 Nov 2016 Celgene Corporation completes a phase I trial in Healthy volunteers in United Kingdom (PO) (NCT02994381)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top